Urine Toxicology Testing to Support Pain Management and Treatment for Substance Use Disorder



 

As controlled substances are prescribed in pain management and addiction treatment settings, urine drug testing is frequently adopted to monitor and assure clinical adherence to treatment plans. The purpose of such testing is to verify expected drug use, in addition to identify unexpected drug use. Because the clinical utility is different from traditional drug of abuse testing, the testing strategy and approaches are designed accordingly to minimize both “false positive” and “false negative” results. Based on the clinical utility of different drugs detected, the analytical workflow can be further adopted to optimize sensitivity and specificity of each individual drug.

Originally published on July 8, 2020


Lecture Presenter

Yifei Yang, PhD, DABCC

Yifei Yang, PhD, DABCC

Medical Director, Toxicology
ARUP Laboratories
Assistant Professor (Clinical) Pathology
University of Utah School of Medicine

Dr. Yang is an assistant professor of pathology at the University of Utah School of Medicine. She received her PhD in pharmacology from Yale University and subsequently completed a postdoctoral fellowship in clinical chemistry at the University of Chicago Medicine. She is a diplomate of the American Board of Clinical Chemistry in clinical chemistry and toxicological chemistry. Dr. Yang’s clinical and research interests are focused on developing and validating new diagnostic assays in therapeutic drug monitoring and proteomics biomarkers.


Objectives

After this presentation, participants will be able to:

  • Describe the general analytical workflow of urine drug testing
  • Explain the testing approaches for medication compliance in pain and addiction management setting
  • Recognize the utilities and limitations of qualitative and quantitative test results
  • Discuss case-based urine drug testing results

Sponsored by:

University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories